Drug intelligence / Profile preview

N-(3-(8-cyano-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazin-2-ylamino)phenyl)acetamide

Development stage
Unknown
Modality
Small Molecules
01

Overview

N-(3-(8-cyano–4–(phenylamino)pyrazolo[1,5-a][1,3,5]triazin–2–ylamino)phenyl)acetamide is a synthetic small molecule belonging to the acetanilides class. It is primarily characterized as a potent and selective inhibitor of casein kinase II subunit alpha (CK2α), an enzyme involved in various cellular processes including cell growth and survival. The compound has been studied experimentally for its binding affinity to CK2α with a reported Ki value of 0.35 nM. There are no approved therapeutic indications or marketed formulations; it remains an experimental research tool for probing CK2 biology and potential anti-neoplastic activity in preclinical settings.[2][4]

Other names
N-[3-{[8-cyano-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}phenyl]acetamideAcetamide,N-[3-{[8-cyano–4-(phenylamino)pyrazolo[1,5-a]-1,3,5-triazin–2–yl]amino}phenyl]
02

Targets

CK2 (Casein kinase II subunit alpha)

Beyond the preview

Go deeper on N-(3-(8-cyano-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazin-2-ylamino)phenyl)acetamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-(3-(8-cyano-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazin-2-ylamino)phenyl)acetamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call